

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017

<https://marketpublishers.com/r/GDD46802793EN.html>

Date: March 2017

Pages: 40

Price: US\$ 2,000.00 (Single User License)

ID: GDD46802793EN

Abstracts

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape.

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.

Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gorlin Syndrome (Basal

Cell Nevus Syndrome) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Overview

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Companies Involved in Therapeutics Development

Adgero Biopharmaceuticals Holdings Inc

Galderma SA

Mayne Pharma Group Ltd

PellePharm Inc

Transgene SA

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Drug Profiles

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-1042 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trifarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Dormant Projects

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Discontinued Products

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Product Development Milestones

Featured News & Press Releases

Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial

Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial

Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment

May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Galderma SA, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Mayne Pharma Group Ltd, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by PellePharm Inc, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Transgene SA, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Dormant Projects, H1 2017

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

I would like to order

Product name: Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/GDD46802793EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDD46802793EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970